Clinical Relevance of Post-Treatment Circulating Tumor DNA Detection in Early Breast Cancer Using a Tissue-Free Epigenomic Assay: A 2-Year Landmark Analysis.
This phase 3 clinical trial evaluated PURPOSE: Circulating tumor DNA (ctDNA) may serve as a biomarker to facilitate early identification of asymptomatic distant tumor spread in patients with breast cancer. Key finding: CONCLUSION: Tissue-free detection of ctDNA 2 years after adjuvant chemotherapy was highly prognostic in an early-stage breast cancer cohort, and can be used to stratify patients with early-stage breast cancer at high risk for recurrence during follow-up who may benefit from early interventions.
This phase 3 clinical trial evaluated PURPOSE: Circulating tumor DNA (ctDNA) may serve as a biomarker to facilitate early identification of asymptomatic distant tumor spread in patients with breast cancer. Key finding: CONCLUSION: Tissue-free detection of ctDNA 2 years after adjuvant chemotherapy was highly prognostic in an early-stage breast cancer cohort, and can be used to stratify patients with early-stage breast cancer at high risk for recurrence during follow-up who may benefit from early interventions.
What the study was
- Study design
- Phase 3 clinical trial
- Category
- Early Detection
- Maturity
- Validated
- Journal
- JCO precision oncology
Why it surfaced
High-priority phase 3 clinical trial in Early cancer detection.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.